ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0478

Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program

Sirisha Gokaraju1, Angus Worthing2, Katherine Maher3, Grace Wright4 and Gail Kerr5, 1Georgetown University hospital, Bethesda, MD, 2Arthritis & Rheumatism Associates, PC, Washington, DC, 3Arthritis & Rheumatism Associates, PC, Alexandria, VA, 4Association of Women in Rheumatology, New York, NY, 5Washington DC VA Medical Center, Washington, DC

Meeting: ACR Convergence 2020

Keywords: Access to care, Biologicals, Cost-Effectiveness, Health Care, Health policy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Professional Education (0474–0478)

Session Type: Abstract Session

Session Time: 10:00AM-10:50AM

Background/Purpose: In 2015, the American College of Rheumatology (ACR) began Advocacy 101 in person-education for Fellows in Training (FIT) and physicians to encourage participation in federal regulatory and legislative issues that relate to access to care, research funding, and contemporaneous matters. However, FIT participation has been undersubscribed, with 50% – 80% of adult and pediatric trainees unexposed, particularly in single-Fellow programs. Though knowledge of the Advocacy process improved by 30%, there was minimal increase in ACR Advocacy awareness (5%), or increased investment in the Rheum PAC® (3%). FIT reported that while in-person training was acceptable, 48% were receptive to on-line training. To date, no web-based Advocacy Training tool exists.

Objective: To evaluate the impact of a web-based Rheumatology Advocacy Training tool on Increasing Awareness in Early Career.

Methods: Early career rheumatologists who attended the 2019 ACR-Advocacy 101 were invited to participate. Email notification for the 9-step, case-based, web-hosted Advocacy training program was sent every 28 days. Content included ACR and other sources of legislative and regulatory material. Tasks related to improving access to care, writing letters of appeals were included. Single multiple-choice questions were assigned to each case scenario, with continuing medical education credit. Participants were invited to 2 web-based teleconferences; 1) at mid-point – to clarify technical questions, 2) at completion – to review and discuss cases, responses, and obtain feedback from participants. Outcomes of pre- and post-questionnaires, completed, correct answers, narrative summations of responses, and suggestions for improvement were collected.

Results: Early Career Rheumatology physicians (≤ 2years) from 9 academic institutions accepted the invitation to participate. Of 20 trainees who started the program, 75% completed all 9 cases. Correct CME answers were scored on 85% of cases. Overall educational quality of content received a mean rating of 4.3 (Likert scare: 1-5). Seven of the 9 cases achieved positive ratings related to relevance of case content, achievement of training goal, objectivity and helping improve competence. Cases relevant to Medicare drug coverage structures, Tele-Health, Biosimilars, Medicare Sequestration, Prior Authorization, and how to translate Advocacy training into action, were rated as having the greatest impact. All cases were assessed free of bias. Feedback indicated ~ 30 minutes was dedicated for completion of each case, and that a combination of skill set and content learning to be most effective. Pre- and post-questionnaire scores indicated significant improvement in knowledge of advocacy matters (p< 0.0001,Table).

Conclusion: A web-based, case-scenario Advocacy tool permitted access to training, increased participation and awareness of pertinent federal regulatory and legislative issues related to the care of rheumatic patients. A follow-up evaluation 2 years post-training to assess enduring Advocacy engagement is planned.

Table 1: Rating of Educational Quality of 9 case scenarios

Table 2: Pre- and Post-course Questionnaire scores for Advocacy Training


Disclosure: S. Gokaraju, None; A. Worthing, None; K. Maher, None; G. Wright, Amgen, 1, 2, Abbvie, 1, 2, Bristol Myers Squibb, 1, 2, Janssen, 1, Myriad, 1, 2, Pfizer, 1, Eli Lilly, 1, 2, UCB, 1, 2, Gilead, 1, Association of Women In Rheumatology, 1, Novartis, 1, 2; G. Kerr, Novartis, 1, BMS, 1, 2, Gilead, 1, Regeneron, 1, Janssen, 1.

To cite this abstract in AMA style:

Gokaraju S, Worthing A, Maher K, Wright G, Kerr G. Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/increasing-awareness-of-advocacy-during-early-career-a-web-based-educational-program/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increasing-awareness-of-advocacy-during-early-career-a-web-based-educational-program/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology